Matches in Wikidata for { <http://www.wikidata.org/entity/Q91861644> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- Q91861644 description "article scientifique publié en 2019" @default.
- Q91861644 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q91861644 description "im Mai 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91861644 description "scientific article published on 05 May 2019" @default.
- Q91861644 description "wetenschappelijk artikel" @default.
- Q91861644 description "наукова стаття, опублікована 5 травня 2019" @default.
- Q91861644 name "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" @default.
- Q91861644 name "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" @default.
- Q91861644 type Item @default.
- Q91861644 label "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" @default.
- Q91861644 label "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" @default.
- Q91861644 prefLabel "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" @default.
- Q91861644 prefLabel "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" @default.
- Q91861644 P1433 Q91861644-FFDD1CF3-E739-40E7-8CBE-FA4E62398BC2 @default.
- Q91861644 P1476 Q91861644-A498EEE0-DCCC-401D-9B3F-B48C0E6658AF @default.
- Q91861644 P2093 Q91861644-0053A1B9-31F7-4A8C-BFA2-FEF1B1AA5434 @default.
- Q91861644 P2093 Q91861644-156DA541-D171-4406-8D85-B70B7BCE6525 @default.
- Q91861644 P2093 Q91861644-16951353-2165-4E5F-8EE4-156B4949A2D9 @default.
- Q91861644 P2093 Q91861644-3D3B485C-A6FC-4AD3-B3FB-1D8CFEC0778E @default.
- Q91861644 P2093 Q91861644-463BBBBA-0E86-4909-B15B-A3B037AA79A4 @default.
- Q91861644 P2093 Q91861644-5152C4DD-389B-4436-BA61-FCE1D358CE83 @default.
- Q91861644 P2093 Q91861644-69EB3F8F-F4BC-4D8B-B4E9-E65BD350DD2D @default.
- Q91861644 P2093 Q91861644-8FE931B0-C8D6-4BBB-9747-3D8EF008410C @default.
- Q91861644 P2093 Q91861644-B3E03C96-3E72-4840-9E9D-AAAB38C00AC9 @default.
- Q91861644 P2093 Q91861644-E24A823D-469A-4A94-AEA0-B8E0AE0DC88E @default.
- Q91861644 P2093 Q91861644-ED9D3966-79C9-4888-9EE3-46CB4C349DC8 @default.
- Q91861644 P2093 Q91861644-F16AD326-CA0D-439C-9A71-8AAE148322DC @default.
- Q91861644 P2093 Q91861644-F3187769-7E3D-4FF6-998B-08BC80EAA7B7 @default.
- Q91861644 P2860 Q91861644-02CC3467-2947-4A8F-ADDF-91EEA3F71995 @default.
- Q91861644 P2860 Q91861644-20111FA5-1816-4457-B249-A19B8C0AF1DD @default.
- Q91861644 P2860 Q91861644-33B449B3-12F5-4457-A31D-AD7953CCB9CA @default.
- Q91861644 P2860 Q91861644-5D3435B3-759A-4577-B7BD-6AC1061542DC @default.
- Q91861644 P2860 Q91861644-5E7F481A-76ED-40DC-8F37-275D6AB9A7FA @default.
- Q91861644 P2860 Q91861644-6248C075-9273-4779-85A6-8696ED8B2128 @default.
- Q91861644 P2860 Q91861644-747DD501-0E3B-476E-98E7-0B967BF61CB6 @default.
- Q91861644 P2860 Q91861644-9316AEE4-E5DD-4F2C-BDDC-F412794ACA1C @default.
- Q91861644 P2860 Q91861644-962E56D3-A0C9-4491-B6D4-834CA3F8C841 @default.
- Q91861644 P2860 Q91861644-C19F408E-BC72-422E-88C2-6798B6519507 @default.
- Q91861644 P2860 Q91861644-EF77638E-C385-4F9E-A700-329519184EC9 @default.
- Q91861644 P304 Q91861644-75CD9647-E79B-424C-8916-C4FF51B976B3 @default.
- Q91861644 P31 Q91861644-639471F7-0B8F-4478-8812-4E98F1B4607E @default.
- Q91861644 P356 Q91861644-CBF435D8-9FA2-464E-8C3F-E665CF9124EC @default.
- Q91861644 P433 Q91861644-BF698E8C-D4DB-4CBC-AB82-78BC02BD58D8 @default.
- Q91861644 P478 Q91861644-AE35D7C1-F38E-4D66-B4AD-D4FBC8B3AA00 @default.
- Q91861644 P50 Q91861644-22756A5E-0311-4775-9F15-CAF601CD9F60 @default.
- Q91861644 P577 Q91861644-CB2EC562-C8FD-41F8-9773-9954BCA959E0 @default.
- Q91861644 P698 Q91861644-89033DE8-33F1-4B7E-A8B6-252DF2BC7E4D @default.
- Q91861644 P921 Q91861644-0D9D8686-12FA-4659-9D8F-3379DD349F96 @default.
- Q91861644 P921 Q91861644-15CAD894-5A80-4369-BAA8-8B7BCC1CC465 @default.
- Q91861644 P921 Q91861644-215C842D-EFD7-4085-8AE8-DC56732BFB84 @default.
- Q91861644 P921 Q91861644-7892B503-6A32-49BD-9E56-60DA5832737F @default.
- Q91861644 P921 Q91861644-D01C3732-C1F2-4BD8-B50D-F4B9CDD6A72B @default.
- Q91861644 P921 Q91861644-E1BA21C9-9ABE-4A5B-BDCE-11CFF8C6BCD2 @default.
- Q91861644 P921 Q91861644-E672654D-D8C3-4D74-887E-358A9764E766 @default.
- Q91861644 P356 S2352-3018(19)30077-3 @default.
- Q91861644 P698 31068270 @default.
- Q91861644 P1433 Q27726035 @default.
- Q91861644 P1476 "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" @default.
- Q91861644 P2093 "Amanda Clarke" @default.
- Q91861644 P2093 "Andrea Antinori" @default.
- Q91861644 P2093 "Axel Baumgarten" @default.
- Q91861644 P2093 "Cynthia Brinson" @default.
- Q91861644 P2093 "David A Wohl" @default.
- Q91861644 P2093 "Debbie Hagins" @default.
- Q91861644 P2093 "Diana Brainard" @default.
- Q91861644 P2093 "Hal Martin" @default.
- Q91861644 P2093 "Melanie A Thompson" @default.
- Q91861644 P2093 "Moti N Ramgopal" @default.
- Q91861644 P2093 "Rima Acosta" @default.
- Q91861644 P2093 "Sean E Collins" @default.
- Q91861644 P2093 "Xuelian Wei" @default.
- Q91861644 P2860 Q36634864 @default.
- Q91861644 P2860 Q37187973 @default.
- Q91861644 P2860 Q37234729 @default.
- Q91861644 P2860 Q38883840 @default.
- Q91861644 P2860 Q40059801 @default.
- Q91861644 P2860 Q40076712 @default.
- Q91861644 P2860 Q40187648 @default.
- Q91861644 P2860 Q40375080 @default.
- Q91861644 P2860 Q40446339 @default.
- Q91861644 P2860 Q58812046 @default.
- Q91861644 P2860 Q64903088 @default.
- Q91861644 P304 "e355-e363" @default.
- Q91861644 P31 Q13442814 @default.
- Q91861644 P356 "10.1016/S2352-3018(19)30077-3" @default.
- Q91861644 P433 "6" @default.
- Q91861644 P478 "6" @default.
- Q91861644 P50 Q88536415 @default.
- Q91861644 P577 "2019-05-05T00:00:00Z" @default.
- Q91861644 P698 "31068270" @default.
- Q91861644 P921 Q155954 @default.
- Q91861644 P921 Q304330 @default.
- Q91861644 P921 Q422604 @default.
- Q91861644 P921 Q422631 @default.
- Q91861644 P921 Q42824827 @default.
- Q91861644 P921 Q6934595 @default.
- Q91861644 P921 Q937224 @default.